Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2020-11-18 Director's Dealing
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Appendix 3Y - Leo Lee 3 pages 219.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including options and shares held before and after the change, nature of the change (lapse and cancellation of options), and other related information. This type of document is a report of personal share transactions by company directors and executives, commonly known as a director's dealing notice. It does not contain financial performance data, management discussion, or other report types. Therefore, the correct classification is Director's Dealing (DIRS). The document length is 4136 characters, which is consistent with a detailed director's dealing notice rather than a brief announcement or a full report.
2020-11-18 English
Lapse of Unlisted Share Options 2 pages 126.5KB
Director's Dealing Classification · 95% confidence The document is an ASX announcement regarding the lapse of unlisted share options due to the resignation of the CEO. It details the number of options lapsed, exercise prices, expiry dates, and remaining options. There is no financial report, earnings data, or management discussion. The document is a specific corporate announcement about share options related to a director's resignation, which fits best under the category of Director's Dealing (DIRS), as it involves share options lapsing due to a director's change in status. The document length is short and focused on this specific event, not a broader report or regulatory filing.
2020-11-18 English
Clarification on Quarterly Activity Report and Appendix 4C 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 11 November 2020 providing a clarification on a previously lodged Quarterly Activity Report and Appendix 4C. It discusses payments to related parties during the quarter and provides additional commentary on executive remuneration. The document is short (1762 characters) and serves as a clarification or update rather than containing full financial statements or substantive financial data. It does not present the quarterly report itself but comments on it. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as it is a general regulatory announcement clarifying prior filings.
2020-11-10 English
CEO Appointment and Resignation 2 pages 125.1KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 2 November 2020 regarding the resignation of the current CEO and appointment of a new CEO at Regeneus Ltd. It details changes in senior management positions, including background information on the new CEO and comments from the Chairman. There is no financial data, no mention of a report or financial results, and the content focuses solely on management changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 3142 characters, which is consistent with a typical management change announcement rather than a full report or presentation.
2020-11-01 English
Material Terms of Contract for Chief Executive Officer 2 pages 67.7KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 2 November 2020 regarding the material terms of contract for the Chief Executive Officer of Regeneus Ltd. It details the appointment of the CEO, remuneration terms, incentives, termination clauses, and other contractual conditions. There is no financial data, no report or presentation, and no voting or dividend information. The content focuses on management appointment and contract terms, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2020-11-01 English
Appendix 4C - Quarterly 7 pages 328.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Quarterly Cashflow report – Period ending 30 September 2020" and includes detailed financial data such as consolidated statements of cash flows, cash balances, receipts, payments, and financing activities for the quarter. It references compliance with ASX Listing Rule 4.7B, which mandates quarterly reporting. The document contains actual financial statements and substantive financial data for a period shorter than a full fiscal year (a quarter). It is not merely an announcement or a brief summary but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2020-10-29 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.